Can-Fite BioPharma Ltd (CANF):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Can-Fite BioPharma Ltd (CANF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3455
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Can-Fite BioPharma Ltd (Can-Fite) is a biopharmaceutical company that offers pharmaceutical discovery and clinical development services. The company’s pipeline product portfolio includes CF101, CF102 and CF602. It develops its products by utilizing its platform technology based on the Gi protein coupled A3 adenosine receptor (A3AR) in inflammatory and cancer cells. Can-Fite developes drugs that are used in the treatment of various diseases such as cancer, sexual dysfunction, inflammatory diseases and ophthalmic indications. The company’s CF 102, is an oral drug used to treat liver cancer and CF 602, is an allosteric modulator used in the treatment of inflammatory diseases. It conducts Phase I, II and III clinical trials for various indications across the US and Israel. Can-Fite is headquartered in Petah-Tikva, Israel.

Can-Fite BioPharma Ltd (CANF) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Can-Fite BioPharma Enters into Distribution Agreement with Gebro Pharma 13
Can-Fite BioPharma Enters into Research Agreement with Hadassah Medical Center 14
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 15
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 16
Merger 17
OphthaliX Merges with Wize Pharma 17
Licensing Agreements 18
CMS Medical Enters into Licensing Agreement with Can-Fite BioPharma 18
Wize Pharma Amends Licensing Agreement with Resdevco 19
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Equity Offering 22
Can-Fite BioPharma to Raise USD5 Million in Private Placement of American Depositary Shares 22
Wize Pharma Files Registration Statement for Public Offering of Shares for up to USD7.5 Million 23
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 24
Wize Pharma Raises USD1 Million in Private Placement of Shares 25
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 26
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 27
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 28
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 29
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 30
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 32
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 33
OphthaliX Withdraws Public Offering of Shares for USD10 Million 34
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 35
Can-Fite BioPharma Ltd – Key Competitors 36
Can-Fite BioPharma Ltd – Key Employees 37
Can-Fite BioPharma Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Strategy And Business Planning 39
Jan 11, 2018: Can-Fite 12 Months’ Activities & Milestones for 2018 39
Financial Announcements 40
Jun 01, 2018: Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update 40
Mar 23, 2018: Can-Fite BioPharma Announces Reports 2017 Financial Results 42
Nov 27, 2017: Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update 44
Sep 01, 2017: Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update 47
May 30, 2017: Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update 49
Mar 31, 2017: Can-Fite Reports 2016 Financial Results & Provides Clinical Update 51
Research And Development 53
Jun 05, 2017: Can-Fite BioPharma establishes clinical advisory board for NAFLD and NASH treatment 53
Other Significant Developments 54
Jan 11, 2018: Can-Fite 12 Months’ Activities & Milestones for 2018 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Can-Fite BioPharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Can-Fite BioPharma Enters into Distribution Agreement with Gebro Pharma 13
Can-Fite BioPharma Enters into Research Agreement with Hadassah Medical Center 14
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 15
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 16
OphthaliX Merges with Wize Pharma 17
CMS Medical Enters into Licensing Agreement with Can-Fite BioPharma 18
Wize Pharma Amends Licensing Agreement with Resdevco 19
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 21
Can-Fite BioPharma to Raise USD5 Million in Private Placement of American Depositary Shares 22
Wize Pharma Files Registration Statement for Public Offering of Shares for up to USD7.5 Million 23
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 24
Wize Pharma Raises USD1 Million in Private Placement of Shares 25
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 26
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 27
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 28
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 29
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 30
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 32
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 33
OphthaliX Withdraws Public Offering of Shares for USD10 Million 34
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 35
Can-Fite BioPharma Ltd, Key Competitors 36
Can-Fite BioPharma Ltd, Key Employees 37
Can-Fite BioPharma Ltd, Other Locations 38
Can-Fite BioPharma Ltd, Subsidiaries 38

List of Figures
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Can-Fite BioPharma Ltd (CANF):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AEON Credit Service (Asia) Co., Ltd.:企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • PhoenixBio Co Ltd (6190):企業の財務・戦略的SWOT分析
    Summary PhoenixBio Co Ltd (PhoenixBio) is a life science company that offers medical therapy solutions. The company offers contract study services including dosing of test-compounds, sampling, chemical analysis, in-life phase trials, measurement of human albumin levels, and metabolic enzymes and blo …
  • Tullow Oil Plc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Tullow Oil Plc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Tullow Oil Plc (Tullow) is an independent upstream oil and gas company. It explores for, develops and produces oil and natural gas in Africa and South America. The company has licenses, both onshore and o …
  • Eutelsat Communications S.A. (ETL):企業の財務・戦略的SWOT分析
    Eutelsat Communications S.A. (ETL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Florida Power & Light Co:電力:M&Aディール及び事業提携情報
    Summary Florida Power & Light Company (FPL), a subsidiary of NextEra Energy, Inc., is a vertically-integrated electric utility that generates, transmits and distributes electricity. The company generates electricity from oil, natural gas, coal, nuclear and solar sources. It also purchases power and …
  • Warimpex Finanz- und Beteiligungs AG:企業の戦略・SWOT・財務情報
    Warimpex Finanz- und Beteiligungs AG - Strategy, SWOT and Corporate Finance Report Summary Warimpex Finanz- und Beteiligungs AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Chiome Bioscience Inc (4583)-製薬・医療分野:企業M&A・提携分析
    Summary Chiome Bioscience Inc (Chiome Bioscience) is a healthcare service company that offers research and development of therapies. The company research and develops antibody drugs for the treatment of autoimmune and inflammatory diseases. Its ADLib system is a monoclonal antibody generating system …
  • Sanquin Blood Supply Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Sanquin Blood Supply Foundation (Sanquin) is a provider of blood bank and diagnostic services, plasma derived products, tissues and cells and reagents. It offers blood-related lab tests for hospitals, blood banks, obstetricians practices, pharmaceutical companies, insurance organizations, an …
  • Samsung Securities Co Ltd (016360):企業の財務・戦略的SWOT分析
    Samsung Securities Co Ltd (016360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Fujirebio Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Fujirebio Diagnostics Inc (FDI), a subsidiary of Fujirebio Inc is a healthcare diagnostic company that develops, manufactures and markets in-vitro diagnostic products and biomarker assays. The company’s products include manual kits, EIA kits, OEM custom solutions, multi-constituent controls, …
  • Basin Electric Power Cooperative:発電所・企業SWOT分析
    Basin Electric Power Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Aptus Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aptus Health Inc (Aptus), formerly Physicians Interactive Inc, a subsidiary of Merck & Co Inc, is a technology company that provides healthcare digital marketing solutions. The company offers strategy, solution design, customer segmentation, advertising, actionable analytic, commercial, paym …
  • EnBW Energie Baden-Wurttemberg AG (EBK):石油・ガス:M&Aディール及び事業提携情報
    Summary EnBW Energie Baden-Wurttemberg AG (EnBW) is an integrated energy company. Through its subsidiaries, the company generates, procures, transmits, and supplies electricity; and produces, transports and supplies gas. It produces electricity in coal, gas, pumped storage, and nuclear power plants. …
  • SACI Falabella:企業の戦略・SWOT・財務情報
    SACI Falabella - Strategy, SWOT and Corporate Finance Report Summary SACI Falabella - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • F. Hoffmann-La Roche Ltd (ROG):企業の財務・戦略的SWOT分析
    F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Vostok New Ventures Ltd (VNV SDB):企業の財務・戦略的SWOT分析
    Summary Vostok New Ventures Ltd (Vostok New Ventures), formerly Vostok Nafta Investment Ltd, is an investment company that identifies and invests in assets. The company carries out partial and complete liquidation of holding and group’s holding companies. It identifies and invests in unlisted compan …
  • Intellia Therapeutics Inc (NTLA):企業の財務・戦略的SWOT分析
    Summary Intellia Therapeutics Inc (Intellia Therapeutics) is a genome editing company that develops proprietary curative therapeutics using CRISPR/Cas9 technology. The company develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, hepatitis B infection, …
  • Franklin Resources Inc:企業の戦略・SWOT・財務分析
    Franklin Resources Inc - Strategy, SWOT and Corporate Finance Report Summary Franklin Resources Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Apotex, Inc.:企業の戦略・SWOT・財務情報
    Apotex, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apotex, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Anthem Inc (ANTM)-製薬・医療分野:企業M&A・提携分析
    Summary Anthem Inc (Anthem), formerly WellPoint Inc, is a health benefits company. It offers several managed healthcare related products and related administrative services. It also provides various specialty and insurance products and services including radiology benefit management, dental, life an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆